Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFA14A
Source: 0000930413-25-001275
Chunk: 7

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFA14A
Chunk 7
---
 vital expertise that is needed at this critical moment – Deep Track’s
campaign would remove proven strategic leadership, essential vaccine expertise, senior public biotechnology and board experience
and deep industry financial expertise. Simply put, Deep Track’s nominees do not stack up.

| Page 5 of 8 |

We remain unwavering in our commitment to act in the
best interests of the Company and all stockholders. Dynavax’s proposed Board slate is uniquely equipped to guide the Company’s
strategy and continue delivering enhanced value for you. Your vote is critical in protecting the future of our Company.

Thank you for your support,

The Dynavax Board of Directors

Advisors

Goldman Sachs & Co. LLC is serving as financial advisor
to Dynavax and Cooley LLP is serving as legal counsel.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing
and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial
products, HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), which is approved in the U.S., the
European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults
18 years of age and older, and CpG 1018 adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19
vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

Forward-Looking Statements

This communication contains “forward-looking” statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking
statements. Forward-looking statements can generally be identified by the use of words such as “anticipate,” “believe,”
“continue,” “expect,” “will,” “may,” “plan,” “potential,”
“seek,” “would” and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking
statements made in this document include statements regarding the Company’s submission of a declassification proposal at
its 2025 Annual Meeting, expected contributions from newly appointed directors, expectations regarding delivering value for our
stockholders, our future growth, our differentiated technology, market share